Gennex Laboratories Limited manufactures and sells bulk drugs, intermediates, and biotech products. The company offers Guaifenesin, an expectorant used as a mucolyte; Methocarbamol for skeletal muscle relaxant; Fexofenadine Hcl for treating antihistamines; Phenazopyridine Hcl for the treatment of urinary tract analgesic; Fluconazole for antifungals; Melitracen Hcl for treating tricyclic antidepressant; Sertraline Hcl, a selective serotonin reuptake inhibitor; Chlorphenesin and Mephenesin for muscle relaxant; and Allopurinol, a xanthine oxidase inhibitor. It has operations in India, Algeria, Bangladesh, Barzil, Bolivia, Colombia, the Czech Republic, Egypt, El Salvador, Germany, Guatemala City, Mexico, Peru, Spain, Turkey, Thailand, the United Arab Emirates, and Vietnam. Gennex Laboratories Limited was formerly known as Prudential Pharmaceuticals Limited and changed its name to Gennex Laboratories Limited in September 2007. Gennex Laboratories Limited was incorporated in 1985 and is base
| Current Price | ₹11.24 |
|---|---|
| Market Cap | ₹273 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Products |
| P/E Ratio | 14.8 |
| Return on Equity | 9.82% |
| 52-Week Range | ₹7.05 – ₹17.25 |
| Beta (1Y) | 0.94 |
Gennex Laboratories Ltd. is trading at ₹11.24, with a market capitalisation of ₹273 Cr.
Gennex Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Products).
Gennex Laboratories Ltd. has a P/E of 14.8 and a return on equity of 9.82%.